Monitoring of treatment with bevacizumab in patients with metastatic colorectal cancer

ABSTRACT: Study hypothesis: Observational study, recording safety according to the National Cancer Institute Common Toxicity Criteria (NCI CTC), version 3.0 and evaluating efficacy in standard clinical practice. Primary outcome(s): 1. Safety of treatment with bevacizumab 2. Response rate: Response Evaluation Criteria in Solid Tumors (RECIST) 3. Rate of radical surgical resection (R0 resection)

DISEASE(S): Metastatic Colorectal Cancer

PROVIDER: 2420410 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR